Non-contact optical meter for diabetes screening in non-clinical settings

用于非临床环境中糖尿病筛查的非接触式光度计

• 批准号: 10034772
• 金额: $ 43.73万
• 依托单位: OCCUITY LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10034772
• 关键词: Non; contact; optical; meter; diabetes

Type 2 diabetes(T2D) is characterised by insulin resistance leading to high blood glucose levels(BG) and affects 4.8mn people in the UK and 422mn globally. Prevalence is rising in most countries; globally 700mn people are predicted to have diabetes, and 374mn pre-diabetes by 2045\. Prediabetes is reversible however, most people aren't diagnosed until they present full diabetes symptoms. Those who don't suspect may never be tested.Costs associated with diabetes and related complications to global health services are ~10% of all government health spending - unsustainable to the point that the WHO now classifies it as a pandemic. Early diagnosis is vital to enable the prevention/management of diabetes when it is relatively inexpensive (healthy diet, physical activity). IDF(International Diabetes Foundation) recommends wide screening of older people. T2D is increasing in children/younger adults, demonstrating a need for broad diabetes screening. However, there is currently no simple and accurate way of doing so.To meet this need Occuity has designed AGE reader; based on research that demonstrates the concentration of Advanced Glycation End-Products (AGEs) within the eye correlates to blood glucose levels and therefore risk of diabetes. AGE reader will be a handheld, non-contact device that shines a blue light into the eye to illuminate the ocular lens and the returning scattered and fluorescent light from the AGEs will be detected and AGE levels and diabetes risk determined. That is cheaper and faster than competitors and requires no blood draws or patient fasting and is compatible with nonclinical settings.This project will develop a TRL3 benchtop device to prove the technical advances to make a functioning meter, provide a route forward to a viable(size, cost, functionality) product and gather data on 'normal' levels of AGE in the lens across ages 18-70\.Our route to market is through external healthcare providers, such as pharmacies, optometrists and opticians who, having benefited financially from implementing screening such as covid and Optical Coherence Tomography (OCT) testing, demand new value-adding screening tools that can be easily administered. Therefore this project will also define appropriate pathways into the NHS optician/optometry community, understanding of the use cases, funding mechanisms and integration requirements for pharmacies, and describe the clinical pathway changes necessary within the NHS to enable a widespread screening program to be adopted, e.g. reimbursement mechanisms.Advances in Occuity's technology will also provide a platform for developing further screening devices (e.g. Amyloid plaques for Alzheimer's disease).

2型糖尿病（T2D）的特点是胰岛素抵抗导致高血糖水平（BG），在英国影响480万人，全球影响4.22亿人。大多数国家的患病率正在上升；预计到2045年，全球将有7亿人患有糖尿病，3.74亿人处于糖尿病前期。前驱糖尿病是可逆的，然而，大多数人直到出现完全的糖尿病症状才被诊断出来。那些不怀疑的人可能永远不会被测试。与糖尿病及相关并发症相关的全球卫生服务费用约占所有政府卫生支出的10%——不可持续，以至于世卫组织现在将其归类为大流行。早期诊断对于预防/管理相对便宜的糖尿病（健康饮食、体育活动）至关重要。国际糖尿病基金会建议对老年人进行广泛的筛查。T2D在儿童/年轻人中呈上升趋势，表明需要进行广泛的糖尿病筛查。然而，目前还没有简单而准确的方法来做到这一点。为了满足这一需求，Occuity设计了AGE阅读器；研究表明，眼内晚期糖基化终产物（AGEs）的浓度与血糖水平相关，因此与糖尿病风险相关。AGE阅读器将是一种手持式非接触式设备，它向眼睛发出蓝光，照亮晶状体，并检测AGEs返回的散射光和荧光灯，从而确定AGE水平和糖尿病风险。这种方法比竞争对手更便宜、更快，不需要抽血，也不需要病人禁食，而且与非临床环境兼容。该项目将开发一款TRL3台式设备，以证明制造功能仪表的技术进步，为可行的（尺寸、成本、功能）产品提供一条路线，并收集18-70岁年龄段镜头中“正常”年龄水平的数据。我们的市场途径是通过外部医疗保健提供商，如药房、验光师和配镜师，他们从实施筛查（如covid和光学相干断层扫描（OCT）测试）中获得了经济利益，需要新的增值筛查工具，这些工具可以轻松管理。因此，该项目还将定义进入NHS验光师/验光社区的适当途径，了解用例、资助机制和药房的整合要求，并描述NHS内必要的临床途径变化，以使广泛的筛查项目得以采用，例如报销机制。Occuity技术的进步也将为开发进一步的筛查设备（例如用于阿尔茨海默病的淀粉样斑块）提供平台。